USPTO serial 79295494
ZAKIRYS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 31, 2021
- Examiner
- SMITH, TARYN E
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with ZAKIRYS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
LABORATORIOS FARMACEUTICOS ROVI, S.A.
ES
Other trademarks owned by LABORATORIOS FARMACEUTICOS ROVI, S.A.
LABORATORIOS FARMACEUTICOS ROVI, S.A.
ES
Other trademarks owned by LABORATORIOS FARMACEUTICOS ROVI, S.A.
LABORATORIOS FARMACEUTICOS ROVI, S.A.
ES
Other trademarks owned by LABORATORIOS FARMACEUTICOS ROVI, S.A.
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical products, namely, tonics being medicines for the treatment of headaches; tranquillizers; soporifics; pharmaceutical preparations, namely, antipsychotics; medicated serums for the treatment of eczema; hormones; oral contraceptives; syringes, vials, cartridges, carpules and ampoules for medical purposes containing pharmaceutical products in the nature of antipsychotics; pharmaceutical implants for delivering insulin, namely, implantable subcutaneous drug delivery devices sold filled with insulin; sustained release medicine implants for delivering contraceptives, namely, implantable subcutaneous sustained release drug delivery devices sold filled with contraceptives; oncological preparations being pharmaceuticals for the treatment of cancer; pharmaceutical preparations for the treatment of diseases of the central nervous system; pharmaceutical preparations for the treatment of hormonal diseases; pharmaceutical preparations for the treatment thrombosis and coagulation diseases; disposable syringes sold pre-filled with pharmaceutical preparations for treatment of central nervous system diseases | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by LABORATORIOS FARMACEUTICOS ROVI, S.A.
- Other trademarks owned by LABORATORIOS FARMACEUTICOS ROVI, S.A.
- Other trademarks owned by LABORATORIOS FARMACEUTICOS ROVI, S.A.
- Other trademarks in Class 005
- Similar marks named ZAKIRYS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 31, 2026 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Aug 31, 2026 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Jun 25, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Feb 2, 2024 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Feb 2, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Feb 2, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 2, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 21, 2022 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Feb 9, 2022 | XXSS | GENERIC MADRID TRANSACTION SENT TO IB | — |
| Feb 9, 2022 | XXCR | GENERIC MADRID TRANSACTION CREATED | — |
| Nov 30, 2021 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Aug 31, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 15, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 15, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 26, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 7, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 5, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 4, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 4, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 6, 2021 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jan 21, 2021 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jan 21, 2021 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Dec 30, 2020 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 29, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 27, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 24, 2020 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Oct 20, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 15, 2020 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Oct 8, 2020 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |